Free

Lethal to Livable: How Gleevec changed cancer care

Actions and Detail Panel

Free

Event Information

Share this event

Date and time

Location

Location

Online event

Event description
Lethal to Livable: How Gleevec changed cancer care

About this event

Twenty years ago, on May 10, 2001, the Food & Drug Administration (FDA) approved Gleevec for use in treating patients with a once-deadly cancer called Chronic Myeloid Leukemia (CML). Since that date, thousands of lives have been saved, and Gleevec has set the stage for other pioneering discoveries in the quest to end cancer as we know it.

Hear from patients whose lives were saved by a breakthrough medication to manage CML; hear Dr. Brian Druker, the physician scientist who pioneered Gleevec, tell how he overcame skepticism on his way to FDA approval; and hear from others at the OHSU Knight Cancer Institute as they talk how Gleevec paved the way for a transformative approach to cancer research and care.

Date and time

Location

Online event

Save This Event

Event Saved